Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS) will report third quarter 2025 financial results and provide business updates on Wednesday, November 12, 2025 at 4:30 p.m. ET. A live webcast of the conference call and presentation will be available in the Events section of Fractyl Health’s investor website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
Positive
- None.
Negative
- None.
News Market Reaction – GUTS
On the day this news was published, GUTS gained 0.89%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $149M at that time.
Data tracked by StockTitan Argus on the day of publication.
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit www.fractyl.com.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
FAQ
When will Fractyl Health (GUTS) report Q3 2025 results?
How can I watch the Fractyl Health (GUTS) Q3 2025 earnings webcast?
Will the Fractyl Health (GUTS) webcast be available after the live event?
What is Fractyl Health (GUTS) focused on?
Where on the Fractyl Health site is the webcast posted for investors?
